Background:
Infections increase the risk of poor outcomes in patients with
ST-elevation myocardial infarction (
STEMI) undergoing
percutaneous coronary intervention (PCI). However, predicting patients at a high risk of developing
infection remains unclear. Moreover, the value of N-terminal probrain
natriuretic peptide (
NT-proBNP) for predicting
infection is still unknown. Thus, we aimed to assess the relationship between
NT-proBNP and the following development of
infection, and clinical adverse outcomes in patients with
STEMI undergoing PCI. Methods:
STEMI patients undergoing PCI were consecutively enrolled from January 2010 to July 2016 and divided into groups according to baseline
NT-proBNP levels: tertiles T1 (<988 pg/mL), T2 (988-3520 pg/mL), and T3 (≥3520 pg/mL). The primary endpoint was
infection during hospitalization. Results: A total of 182 (27%) patients developed in-
hospital infection. The incidence of
infection increased from T1 to T3 (10.5, 17.7, and 54.5%, P < 0.001).
NT-proBNP was an independent risk factor (adjusted odds ratio = 1.39, 95% confidence interval (CI) = 1.12-1.73, P = 0.003) and presented accurately predicting
infection (area under curve = 0.774). Multivariate cox analysis showed that
NT-proBNP was a significant risk factor for major adverse clinical events (
MACE) at follow-up (adjusted HR = 1.92, 95% CI = 1.61-2.29, P < 0.001). Conclusion: The baseline
NT-proBNP level has a good predictive value for
infection and
MACE in
STEMI patients undergoing PCI.